ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0676

Understanding the Patient Burden of Lupus: Insights from Multi-Faceted Ethnography Research

Jeanette Andersen1, Ina Meyer2, Neeta Camadoo3, Tracy Machado4, Shreya Saraf4 and Mohamed Akrout2, 1Lupus Europe, Brussels, Belgium, 2F. Hoffmann-La Roche Ltd, Basel, 3Roche Products Ltd, Welwyn Garden City, 4Elma Research International, London

Meeting: ACR Convergence 2024

Keywords: Access to care, Disparities, Qualitative Research, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: SLE – Treatment Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE or lupus) is a chronic autoimmune disease that affects multiple organs, including the skin, joints, lungs, heart, kidneys and brain. Symptoms vary widely, and disease progression is unpredictable. Lupus significantly impacts daily functioning and overall quality of life (QoL).1 Patients with lupus navigate various personal, medical and social challenges throughout their lives. There is a lack of well-defined diagnostic criteria, and finding effective, well-tolerated treatment options is challenging.

Based on a Patient Benefit Societal Impact insight framework co-created by experts and Roche, this research aimed to explore patient experiences, unmet needs, emotional impacts and daily functional difficulties across different genders, ages, geographies and ethnicities and seek patient-centric strategies to alleviate the burden of lupus.

Methods: The multi-phased research approach started with social media listening and a literature review, followed by in-depth interviews (IDIs) in 9 countries worldwide with people living with lupus (Figure 1) and healthcare providers (Figure 2). Insights from IDIs were discussed in multi-stakeholder workshops to identify potential solutions to key challenges impacting patients with lupus. Identified solutions were validated in an online community (n=61) and ranked in order of priority (Figure 3).

Results: The study revealed significant challenges in the diagnosis process, including misdiagnosis and delays leading to feelings of dismissal and frustration among patients.2-4 Access to appropriate treatment was hindered by long waiting times, limited referral options and incomplete response to current treatments. Lupus profoundly burdened patients’ daily lives, affecting QoL, work productivity and emotional well-being.5 Lack of dietary guidance, inadequate support for family planning, health disparities and limited access to reliable information further compounded the challenges.6-9

Conclusion: Improving lupus care requires timely diagnosis, expert training and expanded specialist access. Enhancing integrated care and streamlining referrals will address treatment delays. Personalized treatment plans, comprehensive support for daily life and mental health and strong patient–provider relationships that foster dialogue, empathy and patient inclusion in decision-making are crucial. Clear dietary recommendations and better communication about family planning and pregnancy are necessary. Addressing health disparities through targeted outreach and equitable access policies will ensure all patients receive the necessary information and care.

References

1. Sutanto B, et al. Arthritis Care Res (Hoboken). 2013;65(11):1752-1765.

2. Cornet A, et al. Lupus Sci Med. 2021;8(1):e000656.

3. Morgan C, et al. Lupus. 2018;27(4):681-687.

4. Daly R, et al. Arthritis Rheumatol. 2017;69(Suppl 10):1-4426.

5. Kent T, et al. Lupus. 2017;26(10):1095-1100.

6. Islam MA, et al. Front Immunol. 2020;11:1477.

7. Rahman A, Isenberg DA. N Engl J Med. 2008;358(9):929-239.

8. Ferguson S, et al. Lupus. 2016;25(1):12-17.

9. Lewis MJ, Jawad AS. Rheumatology (Oxford). 2017;56(suppl_1):i67-i77.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: J. Andersen: F. Hoffmann-La Roche Ltd, 2; I. Meyer: F. Hoffmann-La Roche Ltd, 3; N. Camadoo: Roche Products Ltd, 3; T. Machado: Elma Research International, 3; S. Saraf: Elma Research International, 3; M. Akrout: F. Hoffmann-La Roche Ltd, 3.

To cite this abstract in AMA style:

Andersen J, Meyer I, Camadoo N, Machado T, Saraf S, Akrout M. Understanding the Patient Burden of Lupus: Insights from Multi-Faceted Ethnography Research [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/understanding-the-patient-burden-of-lupus-insights-from-multi-faceted-ethnography-research/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/understanding-the-patient-burden-of-lupus-insights-from-multi-faceted-ethnography-research/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology